By Martin D. Burke
ESI Special Topics,
May 2005
Citing URL - http://www.esi-topics.com/nhp/200/may-05-MartinDBurke.html
|
Martin D. Burke answers a few questions about this month's
new hot paper in the field of Chemistry.
From
•>>May 2005
Field:
Chemistry
Article Title: A planning strategy for diversity-oriented synthesis
Authors: Burke,
MD;Schreiber, SL
Journal: ANGEW CHEM INT ED
Volume: 43
Page: 46-58
Year: 2004
* Harvard Univ, Dept Chem & Chem Biol, Howard Hughes Med Inst, ICCB, 12 Oxford St, Cambridge, MA 02138 USA.
* Harvard Univ, Dept Chem & Chem Biol, Howard Hughes Med Inst, ICCB, Cambridge, MA 02138 USA.
|
Why
do you think you paper is highly cited?
|

“...chemists are beginning to think about how to make diverse collections of unnatural molecules in the laboratory, and then screen them to find new molecules with optimized properties for medicine and science.”
|
|
I am thrilled to learn that our paper in the Dec. 2003 edition of Angew.
Chem. Int. Ed. entitled "A planning strategy for
diversity-oriented synthesis" has been recognized as one of the
"most cited recent papers in the field of Chemistry" by
Thomson-ISI. I think this paper is receiving a lot of attention
because it dares to ask a fascinating and important question:
"Are the regions of chemistry space as defined by natural
products and known drugs, which have been so intensely scrutinized to
date, the best or most fertile regions for discovering small molecules
that modulate macromolecular function in useful ways?"
This question is fascinating because it challenges chemists to
reconsider the fundamental properties of small molecules that allow
them to achieve the extraordinary outcome of selective perturbation
of protein function. The question is important because if the answer
is "no," then it suggests that the potential impact of
small-molecule-mediated perturbation of protein function has been
only minimally realized to date. The significance of such a finding
would be broad and significant, both in the pharmaceutical industry
where small molecule-mediated protein perturbation is used to
promote and restore human health, and in the field of chemical
genetics where small molecule perturbations are used to selectively
modulate and thereby understand complex living systems.
Does
it describe a new discovery or a new methodology that’s useful to
others?
|
|
"To
the left is a photo (click image for a
larger view) that we took during the last step (the 'folding
process') of the diversity-oriented synthesis summarized in
Scheme 10 of the Angewandte Chemie-International Edition
article," says Burke. "In this synthesis, skeletal
diversity was achieved combinatorially by transforming a
collection of substrates having different appendages that
pre-encode skeletal information into a collection of products
having distinct molecular skeletons using common reaction
conditions."
For more
detailed accounts of this synthesis see: M.D. Burke, E.M.
Berger, and S.L. Schreiber. “A Synthesis Strategy
Yielding Skeletally Diverse Small Molecules Combinatorially.” J.
Am. Chem. Soc. 2004, 126, 14095-14014; M.D. Burke., E.M.
Berger, and S.L. Schreiber. “Generating Diverse Skeletons of
Small Molecules Combinatorially.” Science 2003,
302, 613-618). |
A key challenge facing diversity-oriented synthetic chemists is
to prepare collections of unnatural/unprecedented small molecules
having maximized structural complexity and diversity, and the
potential to attach an array of appendages site- and
stereoselectivity during a post-screening, maturation stage. I
believe that this article builds a foundation for a systematic
planning algorithm that aims to assist organic chemists in the
development of efficient synthesis pathways (3-5 steps) that
generate such collections as products.
Could
you summarize the significance of your paper in layman’s terms?
For a long time, the field of organic synthesis has focused on
the challenge of synthesizing, one at a time, the complex molecules
found in nature. Many of these natural molecules are useful as
medicines and tools for science because they cause changes in living
organisms at the molecular level that promote health and
understanding. Recently, chemists have started to question whether
or not the molecules found in nature are really the best ones for
these important applications, that is, might there be unnatural
molecules yet to be discovered that would be more ideally suited for
the job? In order to answer this important question, chemists are
beginning to think about how to make diverse collections of
unnatural molecules in the laboratory, and then screen them to find
new molecules with optimized properties for medicine and science.
Unfortunately, progress in this area has been limited to date,
because preparing diverse collections of unnatural molecules is very
challenging. This article contributes a general and systematic
planning strategy that should assist organic chemists in achieving
this important goal.
How
did you become involved in this research?
I had the privilege of working on this problem during my time as
a graduate student in Professor Stuart Schreiber’s group at
Harvard. Key to the development of this planning strategy for
diversity-oriented synthesis was the recognition that the challenge
of planning the synthesis of a collection of compounds that are
maximally complex and diverse is very different than the challenge
of designing a synthesis pathway to yield a single complex molecular
target. Great progress has been achieved regarding the latter,
including the development of a systematic approach for synthesis
planning, known as "retrosynthetic analysis," in which the
target structure is transformed into a sequence of progressively
simpler structures by formally performing chemical reactions in the
reverse-synthetic direction. The impact of this approach on the
field of target-oriented synthesis has been broad and profound. We
became very excited about the prospect of similarly promoting the
advancement of diversity-oriented synthesis by developing a
complementary planning algorithm customized for the unique
challenges of maximizing structural complexity and diversity.
Martin D. Burke
NIH/MSTP Fellow in the M.D. /Ph.D. Program
Harvard Medical School
Massachusetts Institute of Technology
Department of Health Sciences and Technology
Boston, MA, USA\
As of July 1, 2005, I will be at the following address:
Assistant Professor of Chemistry
University of Illinois
Roger Adams Laboratory
Urbana, IL, USA
|
ESI Special Topics,
May 2005
Citing URL - http://www.esi-topics.com/nhp/2005/may-05-MartinDBurke.html
|
|
|